01—Abstract
Summary
Summary of the 10-K filed February 12, 2024. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation (EW) demonstrated solid performance in its 2023 fiscal year, with net sales reaching $6.0 billiona, an increase of 11.6% year-over-year.
This growth was primarily driven by its Transcatheter Aortic Valve Replacement (TAVR) segment, which accounted for 65%b of total net sales, and a significant 70.1% increase in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment. The company continues to invest heavily in research and development, with 17.8% of net sales dedicated to innovation, particularly in advancing its TAVR and TMTT platforms, including recent FDA approval for its EVOQUE tricuspid valve replacement system. While the company navigated challenges such as COVID-19 impacts and macroeconomic headwinds, its strategic focus on structural heart disease and critical care monitoring remains robust.
A significant event announced in late 2023 was the planned tax-free spin-off of its Critical Care product group, expected by the end of 2024. This strategic move aims to sharpen focus and allow for expanded opportunities within its core structural heart business and interventional heart failure technologies. Investors should note the ongoing significant tax matter with the IRS concerning transfer pricing, which could have future financial implications, though the company is contesting the assessment.
02—Key points
Key Highlights
- Net sales increased by 11.6% to $6.0 billion in 2023, primarily driven by strong performance in the TAVR segment.
- The TMTT segment experienced substantial growth of 70.1%, indicating increasing traction in this newer market.
- The company announced plans to spin off its Critical Care product group, aiming for completion by the end of 2024, to focus on structural heart and heart failure innovations.
- Research and Development spending increased, representing 17.8% of net sales, underscoring a commitment to innovation in key therapeutic areas.
- The EVOQUE tricuspid valve replacement system received FDA approval in February 2024, marking a significant advancement in the treatment of tricuspid regurgitation.
- Despite revenue growth, net income decreased due to an after-tax charge of $134.9 million related to an intellectual property agreement with Medtronic.
- The company faces a significant unresolved tax matter with the IRS regarding transfer pricing, with potential future financial implications.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Edwards Lifesciences kept $0.28.
- Revenue$5.01B100.0%
- Cost of revenue−$978.4M19.5%
- Gross profit$4.03B80.5%
- Operating costs−$2.72B54.3%
- Operating income$1.31B26.1%
- Interest, other & tax$90.5M1.8%
- Net income$1.40B27.9%
Where FY2023 revenue went
$5.01B- SG&A: $1.58B, 32% of revenue
- Operating income: $1.31B, 26% of revenue
- Cost of revenue: $978.4M, 20% of revenue
- R&D: $962.9M, 19% of revenue
- Other operating costs: $177.3M, 3.5% of revenue
Kept 26% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 12, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $5.01B$4.46B | +12.2% |
| Cost of Revenue | $978.40M$723.70M | +35.2% |
| Gross Profit | $4.03B$3.74B | +7.8% |
| R&D Expenses | $962.90M$843.60M | +14.1% |
| SG&A Expenses | $1.58B$1.36B | +16.6% |
| Operating Income | $1.31B$1.50B | −12.6% |
| Interest Expense | $17.60M$19.20M | −8.3% |
| Net Income | $1.40B$1.52B | −8.0% |
| EPS (Basic) | $2.31$2.46 | −6.1% |
| EPS (Diluted) | $2.30$2.44 | −5.7% |
| Shares Outstanding (Basic) | 606.70M619.00M | −2.0% |
| Shares Outstanding (Diluted) | 609.40M624.20M | −2.4% |
05—Questions
Frequently Asked Questions
What were the key drivers of Edwards Lifesciences' sales growth in 2023?
The primary driver of Edwards Lifesciences' sales growth in 2023 was the strong performance of its Transcatheter Aortic Valve Replacement (TAVR) products, which saw increased demand for the Edwards SAPIEN platform, particularly the SAPIEN 3 Ultra RESILIA valve. Additionally, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment experienced significant growth, largely due to the launch and adoption of the PASCAL system in the U.S. and Europe.
What is the significance of the planned spin-off of the Critical Care product group?
The planned spin-off of the Critical Care product group is a strategic move designed to allow Edwards Lifesciences to sharpen its focus on its core structural heart disease business, including TAVR and TMTT, and to pursue new investments in interventional heart failure technologies. This separation is expected to create two more agile and focused entities, potentially unlocking greater value for shareholders.
What are the potential risks or concerns highlighted in the 10-K filing?
Key risks and concerns highlighted include intense competition, the need for continued innovation and successful new product launches, potential manufacturing or quality issues, regulatory hurdles, reliance on third-party suppliers, cybersecurity threats, and significant ongoing litigation and tax matters, particularly the unresolved transfer pricing dispute with the IRS. The company also notes the potential impact of macroeconomic conditions and healthcare cost-containment initiatives.
How did the company's R&D investment perform in 2023?
Edwards Lifesciences increased its R&D spending by 13% year-over-year in 2023, with R&D expenses representing 17.8% of net sales. This investment was primarily directed towards its transcatheter structural heart programs, including clinical research for its mitral, aortic, and tricuspid therapies, reflecting a strong commitment to developing next-generation products and expanding its therapeutic offerings.
06—Continue